Zevra Therapeutics (ZVRA) Competitors $8.04 -0.06 (-0.74%) As of 01/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ZVRA vs. AMPH, WVE, APGE, INDV, GLPG, GPCR, ARQT, EVO, IMCR, and DYNShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Apogee Therapeutics (APGE), Indivior (INDV), Galapagos (GLPG), Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), Evotec (EVO), Immunocore (IMCR), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Amphastar Pharmaceuticals Wave Life Sciences Apogee Therapeutics Indivior Galapagos Structure Therapeutics Arcutis Biotherapeutics Evotec Immunocore Dyne Therapeutics Zevra Therapeutics (NASDAQ:ZVRA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability. Does the media prefer ZVRA or AMPH? In the previous week, Zevra Therapeutics had 3 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 7 mentions for Zevra Therapeutics and 4 mentions for Amphastar Pharmaceuticals. Zevra Therapeutics' average media sentiment score of 1.20 beat Amphastar Pharmaceuticals' score of 0.36 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ZVRA or AMPH? Zevra Therapeutics presently has a consensus target price of $21.57, indicating a potential upside of 168.30%. Amphastar Pharmaceuticals has a consensus target price of $60.33, indicating a potential upside of 65.30%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Zevra Therapeutics is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Amphastar Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, ZVRA or AMPH? Zevra Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Is ZVRA or AMPH more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Zevra Therapeutics' net margin of -342.63%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-342.63% -159.54% -51.50% Amphastar Pharmaceuticals 21.80%26.44%11.89% Which has higher valuation and earnings, ZVRA or AMPH? Amphastar Pharmaceuticals has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$27.46M15.63-$46.05M-$1.97-4.08Amphastar Pharmaceuticals$644.40M2.72$137.54M$3.0012.17 Do insiders and institutionals have more ownership in ZVRA or AMPH? 35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in ZVRA or AMPH? Amphastar Pharmaceuticals received 362 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 66.22% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZevra TherapeuticsOutperform Votes30100.00% Underperform VotesNo VotesAmphastar PharmaceuticalsOutperform Votes39266.22% Underperform Votes20033.78% SummaryAmphastar Pharmaceuticals beats Zevra Therapeutics on 10 of the 19 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$429.18M$6.69B$5.47B$9.21BDividend YieldN/A2.96%5.36%3.98%P/E Ratio-4.089.8788.5517.48Price / Sales15.63318.921,222.4379.63Price / CashN/A65.0944.3037.67Price / Book4.705.265.094.75Net Income-$46.05M$154.64M$117.69M$224.45M7 Day Performance-0.12%4.68%3.23%1.51%1 Month Performance-6.40%2.45%4.13%3.33%1 Year Performance40.07%11.66%28.75%23.25% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.2089 of 5 stars$8.04-0.7%$21.57+168.3%+40.1%$429.18M$27.46M-4.0820Analyst RevisionNews CoveragePositive NewsAMPHAmphastar Pharmaceuticals4.5264 of 5 stars$35.70+0.1%$60.33+69.0%-33.9%$1.72B$723.55M11.901,761WVEWave Life Sciences4.2206 of 5 stars$10.99-2.8%$22.22+102.2%+173.0%$1.68B$53.61M-9.90240APGEApogee Therapeutics1.9354 of 5 stars$37.06+1.0%$89.71+142.1%+15.4%$1.67BN/A-15.3191INDVIndivior2.5699 of 5 stars$11.65-0.1%$16.00+37.3%-32.5%$1.61B$1.09B-291.181,164Positive NewsGLPGGalapagos1.4421 of 5 stars$23.76-0.6%$30.75+29.4%-38.1%$1.57B$260.09M0.001,123Analyst ForecastGPCRStructure Therapeutics1.7014 of 5 stars$27.06+0.3%$81.29+200.4%-29.8%$1.55BN/A-36.57136News CoverageARQTArcutis Biotherapeutics1.4504 of 5 stars$12.68-7.8%$16.60+30.9%+203.7%$1.48B$59.61M-7.08150Positive NewsEVOEvotec2.0839 of 5 stars$4.11+1.7%$5.93+44.4%-47.4%$1.46B$845.74M0.005,061News CoverageGap UpIMCRImmunocore1.7031 of 5 stars$29.02-0.3%$65.64+126.2%-54.0%$1.45B$249.43M-30.55320Analyst RevisionNews CoveragePositive NewsDYNDyne Therapeutics3.5637 of 5 stars$14.13-4.3%$49.91+253.2%-19.1%$1.44BN/A-3.97100Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Amphastar Pharmaceuticals Alternatives Wave Life Sciences Alternatives Apogee Therapeutics Alternatives Indivior Alternatives Galapagos Alternatives Structure Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Evotec Alternatives Immunocore Alternatives Dyne Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZVRA) was last updated on 1/25/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts